Lifecore Biomedical (NASDAQ: LFCR) insider transactions
In the twelve months to 10 November 2026, executives and directors of Lifecore Biomedical reported no open-market sales and no open-market purchases, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 4 June 2026 | Legion Partners, L.P. I | Director | Grant or award | +25,907 | — | 103,482 | Form 4 |
| 4 June 2026 | Obus Nelson | Director | Grant or award | +25,907 | — | 164,100 | Form 4 |
| 4 June 2026 | Houde Lovas Katrina | Director | Grant or award | +25,907 | — | 135,319 | Form 4 |
| 4 June 2026 | Schechter Joshua | Director | Grant or award | +25,907 | — | 133,080 | Form 4 |
| 4 June 2026 | Aryeh Jason | Director | Grant or award | +25,907 | — | 69,967 | Form 4 |
| 4 June 2026 | Korenberg Matthew E | Director | Grant or award | +25,907 | — | 69,967 | Form 4 |
| 4 June 2026 | Antunes Humberto Calheiros | Director | Grant or award | +25,907 | — | 72,967 | Form 4 |
| 4 June 2026 | Johnson Paul Harold | Director | Grant or award | +25,907 | — | 69,967 | Form 4 |
| 20 May 2026 | Josephs Paul | Chief Executive Officer | Shares withheld for tax | −40,413 | $4.57 | 592,915 | Form 4 |
| 14 April 2026 | Salus Thomas D. | Chief Legal & Administration | Shares withheld for tax | −24,645 | $5.20 | 246,333 | Form 4 |
| 2 March 2026 | Salus Thomas D. | Chief Legal & Administration | Grant or award | +30,000 | — | 270,978 | Form 4 |
| 3 September 2025 | Lake Ryan David | Chief Financial Officer | Shares withheld for tax | −22,932 | $7.71 | 336,691 | Form 4 |
| 15 July 2025 | Legion Partners Holdings, LLC | Director | Grant or award | +19,506 | — | 77,575 | Form 4 |
| 15 July 2025 | Houde Lovas Katrina | Director | Grant or award | +19,506 | — | 109,412 | Form 4 |
| 15 July 2025 | Schechter Joshua | Director | Grant or award | +19,506 | — | 107,173 | Form 4 |
| 15 July 2025 | Antunes Humberto Calheiros | Director | Grant or award | +19,506 | — | 47,060 | Form 4 |
| 15 July 2025 | Korenberg Matthew E | Director | Grant or award | +19,506 | — | 44,060 | Form 4 |
| 15 July 2025 | Aryeh Jason | Director | Grant or award | +19,506 | — | 44,060 | Form 4 |
| 15 July 2025 | Johnson Paul Harold | Director | Grant or award | +19,506 | — | 44,060 | Form 4 |
| 15 July 2025 | Obus Nelson | Director | Grant or award | +19,506 | — | 138,193 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Lifecore Biomedical page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.